A detailed history of Lcm Capital Management Inc transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Lcm Capital Management Inc holds 9,830 shares of BMY stock, worth $393,789. This represents 0.35% of its overall portfolio holdings.

Number of Shares
9,830
Previous 9,943 1.14%
Holding current value
$393,789
Previous $510,000 4.51%
% of portfolio
0.35%
Previous 0.37%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 06, 2024

SELL
$47.98 - $54.4 $5,421 - $6,147
-113 Reduced 1.14%
9,830 $533,000
Q4 2023

Feb 05, 2024

SELL
$48.48 - $57.85 $9,599 - $11,454
-198 Reduced 1.95%
9,943 $510,000
Q3 2023

Nov 07, 2023

BUY
$57.89 - $64.73 $5,615 - $6,278
97 Added 0.97%
10,141 $588,000
Q2 2023

Aug 11, 2023

BUY
$63.71 - $70.74 $573 - $636
9 Added 0.09%
10,044 $642,000
Q1 2023

May 01, 2023

BUY
$65.71 - $74.53 $15,704 - $17,812
239 Added 2.44%
10,035 $695,000
Q4 2022

Jan 24, 2023

BUY
$68.48 - $81.09 $1,095 - $1,297
16 Added 0.16%
9,796 $0
Q3 2022

Oct 14, 2022

SELL
$0.13 - $76.84 $2 - $1,459
-19 Reduced 0.19%
9,780 $695,000
Q2 2022

Jul 28, 2022

SELL
$72.62 - $79.98 $18,445 - $20,314
-254 Reduced 2.53%
9,799 $755,000
Q1 2022

Apr 18, 2022

BUY
$61.48 - $73.72 $3,504 - $4,202
57 Added 0.57%
10,053 $734,000
Q4 2021

Jan 24, 2022

BUY
$53.63 - $62.52 $7,776 - $9,065
145 Added 1.47%
9,996 $623,000
Q3 2021

Oct 15, 2021

SELL
$59.17 - $69.31 $9,644 - $11,297
-163 Reduced 1.63%
9,851 $583,000
Q2 2021

Jul 21, 2021

SELL
$61.91 - $67.42 $19,192 - $20,900
-310 Reduced 3.0%
10,014 $669,000
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $32,637 - $36,707
-550 Reduced 5.06%
10,324 $652,000
Q4 2020

May 12, 2021

BUY
$57.74 - $65.43 $627,864 - $711,485
10,874 New
10,874 $677,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $85.2B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Lcm Capital Management Inc Portfolio

Follow Lcm Capital Management Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lcm Capital Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Lcm Capital Management Inc with notifications on news.